Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20924811 | 0.93 | NAAA (0.36) | NAAASMN1; SMN2 | |
| SCHEMBL15009586 | 0.87 | NAAA (0.54) | NAAASMN1; SMN2MAPTMAPK1LMNA | |
| SCHEMBL15027493 | 0.87 | NAAA (0.54) | NAAASMN1; SMN2MAPTMAPK1LMNA | |
| SCHEMBL20924783 | 0.87 | NAAA (0.51) | NAAASMN1; SMN2MAPTMAPK1LMNA | |
| SCHEMBL16376200 | 0.86 | NAAA (0.55) | NAAASMN1; SMN2MAPTMAPK1LMNA | |
| SCHEMBL15026848 | 0.86 | NAAA (0.55) | NAAASMN1; SMN2MAPTMAPK1LMNA | |
| SCHEMBL15009576 | 0.86 | NAAA (0.55) | NAAASMN1; SMN2MAPTMAPK1LMNA | |
| SCHEMBL31323892 | 0.85 | NAAA (0.52) | NAAASMN1; SMN2MAPTMAPK1LMNA | |
| SCHEMBL15028238 | 0.82 | NAAA (0.50) | NAAASMN1; SMN2MAPTMAPK1LMNA | |
| SCHEMBL29190226 | 0.82 | NAAA (0.64) | NAAASMN1; SMN2MAPTMAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2788316-B1 | BRANCHED ALKYL AND CYCLOALKYL TERMINATED BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS INC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-9463247-B2 | Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-9463247-B2 | Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20150005363-A1 | Branched Alkyl And Cycloalkyl Terminated Biodegradable Lipids For The Delivery Of Active Agents | BANK OF AMERICA, N.A. | 2015-01-01 | — | — | US | disclosed |
| US-20150005363-A1 | Branched Alkyl And Cycloalkyl Terminated Biodegradable Lipids For The Delivery Of Active Agents | BANK OF AMERICA, N.A. | 2015-01-01 | — | — | US | disclosed |
| WO-2013086322-A1 | BRANCHED ALKYL AND CYCLOALKYL TERMINATED BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005363-A1 | Branched Alkyl And Cycloalkyl Terminated Biodegradable Lipids For The Delivery Of Active Agents | LIPA, CETP, APOB | NAAA 1178/4885SMN1; SMN2 2502/4885MAPT 3622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.